2-ethoxy-5-pyridinemethaneamine | 591771-82-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-ethoxy-5-pyridinemethaneamine
• 英文别名: (6-ethoxypyridin-3-yl)methanamine
• CAS: 591771-82-3
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: AMCRMLLUWGBHQF-UHFFFAOYSA-N

物化性质

• 沸点：
  255.7±25.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Cyano-3,3-bis-methylsulfanyl-acrylic acid 2-methoxy-ethyl ester 、 2-ethoxy-5-pyridinemethaneamine 以 乙醇 为溶剂， 反应 3.0h， 以70.7%的产率得到2-methoxyethyl (E)-2-cyano-3-[(6-ethoxypyridin-3-yl)methylamino]-3-methylsulfanylprop-2-enoate
  参考文献：
  名称：

  2-氰基-3-取代-吡啶甲基氨基丙烯酸酯的合成和除草活性。

  摘要：

  两个系列的2-氰基-3-取代的吡啶甲基氨基丙烯酸酯，即12种新的（Z）-2-氰基-3-甲硫基-3-取代的吡啶甲烷氨基丙烯酸酯和10种新的（Z）-2-氰基-3-烷基-3-丙烯酸酯取代的吡啶甲烷氨基丙烯酸酯被合成为光系统II（PSII）电子传输的除草抑制剂。所有这些化合物都通过（1）NMR，元素，IR和质谱分析证实。对它们的除草活性进行了评估。一些化合物即使在75 g / ha的剂量下也表现出优异的除草活性。吡啶环的2位上合适的取代基和丙烯酸酯的3位上合适的基团对于高除草活性至关重要。含有取代吡啶环的2-氰基丙烯酸酯比含有苯基的母体化合物具有更高的除草活性。

  DOI：

  10.1021/jf034067s
• 作为产物：
  描述：

  6-乙氧基烟腈 在 氨 、 氢气 、 镍 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以84.3%的产率得到2-ethoxy-5-pyridinemethaneamine
  参考文献：
  名称：

  吡唑并吡啶类化合物或其盐及其制备方法和用途

  摘要：

  本发明涉及吡唑并吡啶类化合物化合物或其盐及其制备方法和用途，尤其涉及其中R1、R2、R3、R4、R5、环A、B、m和n如说明书中所定义的式(I)化合物或者其立体异构体、互变异构体、稳定的同位素衍生物、药学上可接受的盐或溶剂合物，及其制备方法和含有它们的药物组合物，以及所述化合物在制备治疗或预防与RET有关的疾病的药物中的用途。

  公开号：

  CN114181205A

文献信息

• [EN] COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DU RÉCEPTEUR A2B DE L'ADÉNOSINE ET DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2019046784A1

  公开（公告）日：2019-03-07

  Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors. In an aspect is provided a method of inhibiting Adenosine A2B Receptor activity and Adenosine A2A Receptor activity, the method including contacting the Adenosine A2B Receptor and Adenosine A2A Receptor with a compound as described herein, including embodiments.

  在此披露的内容包括调节腺苷受体的组合物和方法。在一个方面，提供了一种抑制腺苷A2B受体活性和腺苷A2A受体活性的方法，该方法包括将腺苷A2B受体和腺苷A2A受体与本文描述的化合物接触，包括各种实施方式。
• Quinazolines as MMP-13 inhibitors
  申请人：——

  公开号：US20020193377A1

  公开（公告）日：2002-12-19

  A compound selected from those of formula (I): 1 in which: R 1 represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, aryl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted, W represents oxygen, sulfhur, or ═N—R′, in which R′ is as defined in the description, X 1 , X 2 and X 3 represent nitrogen or —C—R 6 in which R 6 is as defined in the description, Y represents oxygen, sulfhur, —NH, or —N(C 1 -C 6 )alkyl, Z represents oxygen, sulfhur, —NR 7 in which R 7 is as defined in the description, and 59 optionally carbon atom, n is an integer from 1 to 8 inclusive, Z 1 represents —CR 8 R 9 wherein R 8 and R 9 are as defined in the description, A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system, m is an integer from 0 to 7 inclusive, the group(s) R 2 is (are) is as defined in the description, R 3 represents hydrogen, alkyl, alkenyl, alkynyl, ot a group of formula: 2 in which Z 2 , B, R 5 , P and q are as defined in the description, optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.

  从以下化学式（I）中选择的一种化合物： 其中： R1代表从氢、氨基、烷基、烯基、氨基烷基、芳基、芳基烷基、杂环和环烷基烷基中选择的基团，可选择取代； W代表氧、硫或═N—R′，其中R′如描述中定义； X1、X2和X3代表氮或—C—R6，其中R6如描述中定义； Y代表氧、硫、—NH或—N（C1-C6）烷基； Z代表氧、硫、—NR7，其中R7如描述中定义，且可选地是碳原子； n为1到8之间的整数； Z1代表—CR8R9，其中R8和R9如描述中定义； A代表芳香或非芳香、杂环或非杂环环系统； m为0到7之间的整数； R2代表如描述中定义的基团； R3代表氢、烷基、烯基、炔基或化学式2中的基团： 其中Z2、B、R5、P和q如描述中定义； 可选地，它们的外消旋体、异构体、N-氧化物和药学上可接受的盐，以及含有它们的药物制剂，可用作特异性抑制剂13型基质金属蛋白酶。
• Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
  申请人：——

  公开号：US20040019053A1

  公开（公告）日：2004-01-29

  This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

  该发明提供了一种组合物，包括MMP-13的变构羧酸抑制剂或其药用盐，与Celecoxib或其药用盐，或Valdecoxib或其药用盐。该发明还提供了一种治疗对MMP-13和环氧合酶-2抑制敏感的疾病的方法，包括向患有这种疾病的患者施用包括MMP-13的变构羧酸抑制剂或其药用盐，与Celecoxib或其药用盐，或Valdecoxib或其药用盐的组合物。该发明还提供了一种药物组合物，包括包括MMP-13的变构羧酸抑制剂或其药用盐，与Celecoxib或其药用盐，或Valdecoxib或其药用盐的组合物，以及药用载体、稀释剂或赋形剂。该发明组合物还可以根据所治疗的疾病进一步与其他药物代理结合。
• Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
  申请人：——

  公开号：US20040019054A1

  公开（公告）日：2004-01-29

  This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.

  本发明提供一种组合物，包括MMP-13的变构羧酸抑制剂或其药用盐，以及COX-2的选择性抑制剂或其药用盐，但不包括司来昔布或瓦来昔布。本发明还提供一种治疗对MMP-13和环氧合酶-2抑制响应的疾病的方法，包括向患有该疾病的患者施用包括MMP-13的变构羧酸抑制剂或其药用盐，以及COX-2的选择性抑制剂或其药用盐的本发明组合物，但不包括司来昔布或瓦来昔布。本发明还提供一种药物组合物，包括MMP-13的变构羧酸抑制剂或其药用盐，以及COX-2的选择性抑制剂或其药用盐的本发明组合物，但不包括司来昔布或瓦来昔布，以及药用载体、稀释剂或赋形剂。本发明还提供一种组合物，包括NSAID或其药用盐，以及MMP-13的变构羧酸抑制剂或其药用盐。本发明还提供一种药物组合物，包括MMP-13的变构羧酸抑制剂或其药用盐，以及NSAID或其药用盐的本发明组合物，以及药用载体、稀释剂或赋形剂。本发明还提供一种治疗对MMP-13和环氧合酶-1或环氧合酶-2抑制响应的疾病的方法，包括向患有该疾病的患者施用包括MMP-13的变构羧酸抑制剂或其药用盐，以及NSAID或其药用盐的本发明组合物。根据所治疾病的不同，本发明组合物也可以与其他药物组合。
• [EN] 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES SUBSTITUES EN POSITION 6 EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
  申请人：LILLY CO ELI

  公开号：WO2005082859A1

  公开（公告）日：2005-09-09

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.

  本发明提供了公式I中的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症/强迫性障碍、抑郁症和焦虑症：I其中：R6为-C=C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。